Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

NCT02526160 is registered in ClinicalTrials.gov with Kyowa Kirin, Inc. as lead sponsor.

NCT NCT02526160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02526160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Lead sponsor
Kyowa Kirin, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 22, 2015
Completion date
December 6, 2018
Enrollment
134 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked hypophosphatemia